Drugs / FS VH S/D 500 s-apr
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00681824 | May 2008 → Mar 2010 | craniofacial and skeletal defects | Baxter Healthcare Corporation | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FS VH S/D 500 s-apr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00681824 ↗ |
| Modality | Protein / enzyme biologic | “a double virus-inactivated biological two-component fibrin sealant” NCT00681824 ↗ |
| Route | Topical | “Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area” NCT00681824 ↗ |